Searchable abstracts of presentations at key conferences in endocrinology

ea0086oc2.4 | Endocrine Cancer and Late Effects | SFEBES2022

Delta-like non-canonical Notch ligand 1 (DLK1) – a novel biomarker in adrenocortical carcinoma

Pittaway James , Mariniello Katia , Altieri Barbara , Sbiera Iuliu , Sbiera Silviu , Chung Teng-Teng , Abdel-Azziz Tarek , DiMarco Aimee , Palazzo Fausto , Akker Scott A. , Landwehr Laura-Sophie , Ronchi Cristina , Parvanta Laila , Drake William , Kroiss Matthias , Fassnacht Martin , Guasti Leonardo

Adrenocortical carcinoma (ACC) is a rare malignancy with limited treatment options and a heterogenous prognosis. The histological diagnosis of ACC is complex and there is increasing interest in identifying and validating new immunohistochemical markers. Delta-like non-canonical Notch ligand 1 (DLK1) is a cleavable single-pass transmembrane protein. In humans, DLK1 is present in many tissues during foetal development, is restricted to progenitor/stem cells in a few adult tissue...

ea0049gp121 | Endocrine Tumours | ECE2017

Immunity in adrenocortical carcinoma patients – interplay between anti-cancer immunity and steroid hormones

Sbiera Silviu , Dexneit Thomas , Sbiera Iuliu , Schreiner Jochen , Ronchi Cristina L. , Kroiss Matthias , Fassnacht Martin

Adrenocortical carcinoma (ACC) is one of the most aggressive endocrine malignancies. By applying a ‘multiple omics’ approach, we recently identified two distinct subgroups of ACC patients, a good prognosis “immune” and bad prognosis “steroid” phenotype.We hypothesized that the steroid phenotype is associated with glucocorticoid-induced suppression that can be ‘rescued’ by reactivating the immune system using immune...

ea0070oc1.4 | Adrenal and Cardiovascular Endocrinology | ECE2020

Immune infiltrate and PD-1 / PD-L1 expression in adrenocortical carcinoma: who can predict patients´ outcome?

Landwehr Laura-Sophie , Sbiera Iuliu , Schreiner Jochen , Weigand Isabel , Kroiss Matthias , Fassnacht Martin , Sbiera Silviu

Context: Adrenocortical carcinoma (ACC) are endocrine malignant neoplasms associated with severe aggressiveness. Tumour-related glucocorticoid excess occurs in 60% of patients and is associated with poor prognosis. First clinical trials using immune checkpoint inhibitors are quite unsatisfactory and treatment advancements are urgently needed.Recently, we characterized tumour-infiltrating lymphocytes (TILs) in ACC and identified the detrimental dependency...

ea0081p385 | Endocrine-Related Cancer | ECE2022

PD-1 and PD-L1 immune checkpoint expression - the prognostic impact on adrenocortical carcinoma

Landwehr Laura-Sophie , Sbiera Iuliu , Altieri Barbara , Remde Hanna , Kircher Stefan , Sbiera Silviu , Kroiss Matthias , Fassnacht Martin

Adrenocortical carcinoma (ACC) is a very severe endocrine malignancy with poor prognosis. While cancer immunotherapies have revolutionized the treatment of several cancer entities, the results of initial studies of different immune checkpoint inhibitors in ACC were heterogeneous and clinically substantial responses were observed only in a subset of patients. Expression of immune checkpoint molecules - programmed cell death 1 (PD-1) and its ligand PD-L1 - has been shown to pred...

ea0063p460 | Adrenal and Neuroendocrine Tumours 2 | ECE2019

Steroid hormones and cancer immunity - insights into adrenocortical carcinoma

Landwehr Laura-Sophie , Dexneit Thomas , Herterich Sabine , Sbiera Iuliu , Schreiner Jochen , Kroiss Matthias , Fassnacht Martin , Sbiera Silviu

Context: Adrenocortical carcinoma (ACC) are endocrine malignant neoplasms associated with severe aggressiveness. By applying of ‘multiple omics’ approach, we recently categorized ACC patients based on their steroidogenic activity and expression of immune activation marker, which is along with prognosis; an ‘immune’ phenotype with good and a ‘steroid’ phenotype with bad outcome.Hypothesis: Our central hypothesis focuses on th...

ea0049gp22 | Adrenal 3 | ECE2017

Epithelial to mesenchymal transition in adrenocortical tumours: focus on FGF-FGFR pathway and c-MET

Sbiera Iuliu , Altieri Barbara , Feuchtinger Annette , Hofner Kerstin , Walch Axel , Fassnacht Martin , Ronchi Cristina L , Kroiss Matthias , Sbiera Silviu

Ad Adrenocortical carcinoma (ACC) is an aggressive tumour and treatment remains unsatisfactory in advanced disease. Activation of epithelial to mesenchymal transition (EMT) is considered causative for metastatic spread in a variety of human cancers. Accordingly, new drugs were developed specifically targeting EMT with a focus on hepatocyte growth factor (HGF)/HGF receptor (c-MET) and fibroblast growth factor (FGF)/FGF receptor (FGFR) signalling.We here a...

ea0070aep3 | Adrenal and Cardiovascular Endocrinology | ECE2020

Is there an epithelial to mesenchymal transition (EMT) in adrenocortical tumours?

Sbiera Iuliu , Kircher Stefan , Feuchtinger Annette , Höfner Kerstin , Karl Walch Axel , Fassnacht Martin , Kroiss Matthias , Sbiera Silviu

Introduction: Adrenocortical carcinoma (ACC) is an aggressive tumour with unsatisfactory treatment options in advanced disease. Activation of epithelial to mesenchymal transition (EMT) has been described as causative of metastatic spread in human cancers. New drugs were developed targeting EMT with a focus on FGF/FGFR signalling. We here asked whether EMT is relevant in ACC.Methods: We analysed 6 normal adrenal glands (NAG), 40 adrenocortical adenomas (A...

ea0093oc19 | Oral communication 3: Adrenal Tumors and Neuroendocrine Tumors | EYES2023

FGF/FGFR signaling in adrenocortical tumorigenesis: Novel potential therapeutic targets in adrenocortical carcinoma

Kappenstein Lena , Paul Alexander , Altieri Barbara , Sbiera Iuliu , Sandra Sigala , Alfredo Berruti , Fassnacht Martin , Sbiera Silviu , Tamburello Mariangela

Background: Adrenocortical carcinoma (ACC) is one of the most aggressive endocrine malignancies. The Fibroblast Growth Factor/Fibroblast Growth Factor Receptor (FGF/FGFR) pathway plays a role in both embryogenesis and tumorigenesis of adrenal gland. Our group demonstrated that FGFR1-4 were upregulated in ACCs and that their high expression was significantly associated with worse prognosis, suggesting that they are potentially interesting therapeutic targets.<p class="abste...

ea0056p134 | Endocrine tumours and neoplasia | ECE2018

Mesenchymal tissue markers as potential drug targets in adrenocortical tumours

Sbiera Iuliu , Altieri Barbara , Feuchtinger Annette , Kircher Stefan , Hofner Kerstin , Walch Axel Karl , Fassnacht Martin , Ronchi Cristina L , Kroiss Matthias , Sbiera Silviu

Introduction: Adrenocortical carcinoma (ACC) is a rare, aggressive tumour with unsatisfactory treatment options in advanced disease. Activation of epithelial to mesenchymal transition (EMT) has been described as causative of metastatic spread in a variety of human cancers. Accordingly, new drugs were developed specifically targeting EMT with a focus on HGF/c-MET and FGF/FGFR signalling. We here asked whether EMT is a relevant mechanism in ACC.Methods: Ex...